Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 EUR | 0.00% | -9.47% | +18.39% |
Jun. 14 | Mib down; political instability weakens euro | AN |
Jun. 04 | Futures down; focus on ECB cuts | AN |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in debt and has limited leeway for investment
- The firm trades with high earnings multiples: 30.41 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.23 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.39% | 1.25B | B | ||
+10.52% | 27.46B | B+ | ||
+32.96% | 2.6B | B | ||
-42.44% | 2.58B | B- | ||
+8.22% | 2.24B | - | A- | |
-26.44% | 2.21B | C+ | ||
+30.00% | 1.99B | B | ||
-8.95% | 1.91B | - | ||
+35.14% | 1.35B | C | ||
0.00% | 1.29B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GVS Stock
- Ratings GVS S.p.A.